Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04171817 · ClinicalTrials.gov registry record · Phase 4

Animal-Assisted Visitation Program Chlorhexidine Trial

A Phase 4 study, sponsored by Johns Hopkins Bloomberg School of Public Health.

Completed
Registry status
Phase 4
Development phase
45
Enrollment target

NCT04171817 is a Phase 4 study that has completed, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 45 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04171817, a Phase 4 study, has completed, sponsored by Johns Hopkins Bloomberg School of Public Health.

COMPLETED
Registry status
Phase 4
Development phase
45 participants
Enrollment target

Study Summary

Hospital-based Animal-Assisted visitation programs are important complementary therapies, but concerns with infection control may challenge the sustainability of these programs. Pilot data suggest that a low-cost chlorhexidine-based intervention targeted to the dogs involved in the visitation programs holds high potential to prevent pathogen transmission during sessions. In this study, the following aims will be tested: 1) To identify program-related risk factors for acquisition of hospital-associated pathogens by pediatric patients during animal-assisted intervention (AAI) sessions during an initial run-in phase of no intervention; 2) To determine the effect of chlorhexidine (CHX)-based interventions on acquisition of hospital-associated pathogens and microbial communities by patients during AAI sessions via a multicenter randomized controlled trial; and 3) To determine whether the specific benefits achieved by the visitation program, i.e. reduction in blood pressure, heart rate and self-reported pain and anxiety, are impacted by the interventions.

Interventions

  • DRUG Chlorhexidine

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2023-05-01
Est. Completion 2026-04-01
Phase Phase 4

What the Registry Record Tells You About NCT04171817

The ClinicalTrials.gov registry entry for NCT04171817 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins Bloomberg School of Public Health, which has 187 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Chlorhexidine is the first listed.

NCT04171817 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04171817 about?

NCT04171817 is a clinical study titled "Animal-Assisted Visitation Program Chlorhexidine Trial". Hospital-based Animal-Assisted visitation programs are important complementary therapies, but concerns with infection control may challenge the sustainability of these programs. Pilot data suggest that a low-cost chlorhexidine-based intervention targeted to the dogs involved in the visitation progra...

What is the current status of trial NCT04171817?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2023-05-01. Estimated completion is 2026-04-01.

What interventions are being tested in trial NCT04171817?

The interventions under investigation include: Chlorhexidine (DRUG).

Who is sponsoring clinical trial NCT04171817?

This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.